✦ LIBER ✦

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

✍ Scribed by S. George; J.Y. Blay; P.G. Casali; A. Le Cesne; P. Stephenson; S.E. DePrimo; C.S. Harmon; C.N.J. Law; J.A. Morgan; I. Ray-Coquard; V. Tassell; D.P. Cohen; G.D. Demetri

Book ID: 116429988
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 523 KB
Volume: 45
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2009.02.011

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of sunitinib in pati

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

✍ George D Demetri; Allan T van Oosterom; Christopher R Garrett; Martin E Blackste 📂 Article 📅 2006 🏛 The Lancet 🌐 English ⚖ 201 KB

Phase II study of dovitinib in patients

Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib

✍ Kang, Y-K; Yoo, C; Ryoo, B-Y; Lee, J J; Tan, E; Park, I; Park, J H; Choi, Y J; J 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 682 KB

Comparison of performance of various tum

Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib

✍ Shinagare, Atul B.; Jagannathan, Jyothi P.; Kurra, Vikram; Urban, Trinity; Manol 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 409 KB

7501 ORAL Continuous daily dosing (CDD)

7501 ORAL Continuous daily dosing (CDD) study of sunitinib malate (SU) in patients (pts) with advanced GIST compares favorably with intermittent dosing

✍ Blay, J.Y.; George, S.; Casali, P.G.; Le Cesne, A.; Morgan, J.A.; Pokela, J.; Qu 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Discontinuation of imatinib in patients

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial

✍ Axel Le Cesne; Isabelle Ray-Coquard; Binh Nguyen Bui; Antoine Adenis; Maria Rios 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 293 KB

Outcome of patients with advanced gastro

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg

✍ John R. Zalcberg; Jaap Verweij; Paolo G. Casali; Axel Le Cesne; Peter Reichardt; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 128 KB